Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 open-label study of D-1553 in advanced or metastatic solid tumors with KRAS G12C mutation
CTR20220745Phase 2Active
- Sponsor
- InventisBio
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of garsorasib in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), sponsored by InventisBio. Started Jun 2022; status: active.
02
Drugs
garsorasib
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20220745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220745.